Clinical trials: Amyotrophic Lateral Sclerosis (ALS), open to volunteers
Amyotrophic Lateral Sclerosis
EIM Via the Myolex mScan as an ALS Biomarker
Amyotrophic lateral sclerosis (ALS) has been traditionally considered incurable and untreatable. But starting in the 1990s with the introduction of Riluzole, therapies are being discovered and ultimately approved for slowing…
- Trial name
- ElectricALS (NCT06491732)
- Testing
- Electrical Impedance Myography
- Where
- 6 sites in United States
- Volunteers
- 80 people
- Sponsor
- Beth Israel Deaconess Medical Center
Tetraplegia/Tetraparesis, Amyotrophic Lateral Sclerosis (ALS)
Control of Assistive Devices Via Brain-Computer Interface Technology
The CONVOY Study is a clinical trial designed to explore the feasibility of participants from the PRIME Study (NCT06429735) using the N1 Implant to control various assistive devices.
- Conditions
- Tetraplegia/Tetraparesis, Amyotrophic Lateral Sclerosis (ALS), Quadriplegia, Spinal Cord Injury (SCI)
- Trial name
- CONVOY (NCT06710626)
- Testing
- Assistive Robotic Arm
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Neuralink Corp
Parkinson's Disease (PD), Alzheimer's Disease (AD)
Quantification of Hsp90 in the Human Brain
This study tests the radiolabeled molecule ("tracer"), [¹¹C]HSP990, using positron emission tomography (PET) imaging to assess whether it can be used to measure levels of Heat Shock Protein 90 (Hsp90).
- Conditions
- Parkinson's Disease (PD), Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS)
- Trial name
- NCT07380204
- Testing
- [11C]HSP990 PET dosimetry, [11C]HSP990 PET test-retest, [11C]HSP990 simplified scan protocol
- Where
- Belgium
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Amyotrophic Lateral Sclerosis
Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone
This study is being conducted to help the investigators better understand how the new FDA approved medication Edaravone (also known as Radicava) works in subsets of patients with ALS.
- Trial name
- NCT04097158
- Testing
- Sample Collection
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Loma Linda University
Adjustment Disorder
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to…
- Trial name
- NCT07002034
- Testing
- RE104 for Injection
- Where
- 32 sites in United States
- Volunteers
- 100 people
- Sponsor
- Reunion Neuroscience Inc
Parkinson's Disease; Amyotrophic Lateral Sclerosis; Glioblastoma; Cancer Without Neurological Disease; Rheumatoid Polyarthritis
Control Cohort CTRL COH
Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare disease that could be difficult to diagnose.
- Trial name
- CTRL COH (NCT05370079)
- Testing
- Collection of biological sample (blood and/or CSF)
- Where
- France
- Volunteers
- 350 people
- Sponsor
- Hospices Civils de Lyon
Amyotrophic Lateral Sclerosis (ALS)
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS
Amyotrophic Lateral Sclerosis (ALS) is a severe and incurable neurodegenerative disease of motor neurons with a dramatic socio-economic impact on the national health system.
- Trial name
- PERMEALS (NCT06917924)
- Testing
- lumbar puncture
- Where
- 4 sites in Italy
- Volunteers
- 200 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
ALSFTD, ALS (Amyotrophic Lateral Sclerosis)
Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients
The aim of this study is to assess the impact of a probiotic formulation on participants with ALS-FTDSD. It is hypothesized that participants given the probiotics will have different lipid profiles compared to participants…
- Conditions
- ALSFTD, ALS (Amyotrophic Lateral Sclerosis), Frontal Temporal Dementia (FTD)
- Trial name
- PROBIOTIC (NCT06051123)
- Testing
- Probiotic
- Where
- 3 sites in Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Amyotrophic Lateral Sclerosis, Home Mechanical Ventilation
Development in Home Mechanical Ventilation for Patient With Amyotrophic Lateral Sclerosis.
The aims of the study are to calculate the positive predictive value (PPV) of the codes for home mechanical noninvasive and invasive ventilation in patients with Amyotrophic lateral sclerosis in Denmark, and to describe the…
- Trial name
- NCT07819890
- Volunteers
- 400 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
ALS (Amyotrophic Lateral Sclerosis)
This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling
Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive neurodegenerative disorder characterized by loss of upper and lower motor neurons, leading to muscle weakness, respiratory decline, and eventual mortality.
- Trial name
- NCT07321860
- Testing
- Galunisertib + Nerandomilast Combination
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Gipfel Life Sciences GmbH
Amyotrophic Lateral Sclerosis
Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Sclerosis
The specific aim of this study is to try to discover the diagnostic accuracy of SleepImage technology for detecting respiratory failure in patients with MND.
- Trial name
- NCT07502677
- Testing
- SleepImage
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Amyotrophic Lateral Sclerosis
Needs of ALS Patients With C9orf72 Mutation and Their Caregivers
Individuals with Amyotrophic Lateral Sclerosis (ALS) carrying the C9orf72 HRE mutation (C9Pos) often exhibit different phenotypic traits compared to other patients (C9Neg), presenting a more aggressive form of the disease, with…
- Trial name
- C9survALS (NCT07302321)
- Testing
- Survey for ALS patients, Survey for Caregivers
- Where
- 3 sites in Italy
- Volunteers
- 208 people
- Sponsor
- Istituto Auxologico Italiano
Amyotrophic Lateral Sclerosis
Spinal Cord Associative Plasticity for ALS
Veterans are at higher risk than non-Veterans of falling ill with amyotrophic lateral sclerosis (ALS). The investigators have shown that synchronized stimulation over the brain and cervical spinal cord can temporarily strengthen…
- Trial name
- NCT06172621
- Testing
- Spinal Cord Associative Plasticity (SCAP), Upper extremity task-oriented exercise
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- VA Office of Research and Development
Amyotrophic Lateral Sclerosis
Studies in Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Motor Neuron Disorders
The purpose of this study is to collect, from patients with sporadic and familial ALS and their family members, clinical data and blood samples for extraction of DNA, RNA, preparation of lymphocytes, plasma and serum to establish…
- Trial name
- NCT05474235
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Anarthria, Dysarthria
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)
The goal of this study is to improve our understanding of speech production, and to translate this into medical devices called intracortical brain-computer interfaces (iBCIs) that will enable people who have lost the ability to…
- Conditions
- Anarthria, Dysarthria, Tetraplegia, Spinal Cord Injuries
- Trial name
- BG-Speech-02 (NCT06094205)
- Testing
- BrainGate Neural Interface System
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Leigh R. Hochberg, MD, PhD.
Parkinson Disease Psychosis, Amyotrophic Lateral Sclerosis (ALS)
A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics and pharmacodynamics of oral doses of FB418 in healthy adult subjects and healthy elderly subjects.
- Trial name
- NCT05995782
- Testing
- FB418
- Where
- South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- 1ST Biotherapeutics, Inc.
Spinal Cord Injury, Amyotrophic Lateral Sclerosis
iBCI Optimization for Veterans With Paralysis
VA research has been advancing a high-performance brain-computer interface (BCI) to improve independence for Veterans and others living with tetraplegia or the inability to speak resulting from amyotrophic lateral sclerosis…
- Conditions
- Spinal Cord Injury, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked-in Syndrome
- Trial name
- NCT05470478
- Testing
- Mobile neural decoding platform (mobile iBCI)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- VA Office of Research and Development
Amyotrophic Lateral Sclerosis
Genetic Study of Amyotrophic Lateral Sclerosis in Norway
The purpose of this study is to explore the genetic causes relevant for ALS development in Norway.
- Trial name
- GAIN (NCT05119387)
- Testing
- Observation
- Where
- 17 sites in Norway
- Volunteers
- 1,200 people
- Sponsor
- Sykehuset Telemark
ALS (Amyotrophic Lateral Sclerosis)
Augmented Reality BCI Longitudinal Study for Persons With Late Stage ALS
The goal of this study is refine the usability of a BCI based communication platform. The study will take place in the greater Los Angeles area and will enroll up to 10 participants with late stage ALS.
- Trial name
- NCT06810219
- Testing
- Cognixion ONE
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Cognixion
Amyotrophic Lateral Sclerosis (ALS)
Personalized Antisense Oligonucleotide Therapy for Participants With TARDBP ALS
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for participants with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in TARDBP.
- Trial name
- NCT07743268
- Testing
- nL-TARDB-006
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- n-Lorem Foundation